高收入国家无家可归者精神障碍患病率:更新版系统综述与meta回归分析
该系统综述与meta分析更新了2007年综述,检索截至2021年4月1日,纳入39篇文献共8049名明确界定的高收入国家无家可归者。任何当前精神障碍的平均患病率为76.2%(95%CI 64.0%至86.6%),酒精使用障碍36.7%、药物使用障碍21.7%最常见。研究间异质性大,部分由抽样方法、研究地点和性别分布解释。
要点
- 无家可归者任何当前精神障碍平均患病率高达76.2%。
- 酒精使用障碍36.7%、药物使用障碍21.7%为最常见诊断类别。
- 精神分裂症谱系障碍12.4%、重性抑郁12.6%亦较常见。
核心结论
- 无家可归者精神疾病负担重大,服务规划应特别关注物质使用障碍和精神分裂症谱系障碍。
研究设计与样本
- 系统综述与meta分析,更新2007年综述,检索Medline、Embase、PsycInfo和Google Scholar至2021年4月1日。
- 纳入39篇观察性研究,共8049名明确界定的高收入国家无家可归者,采用标准化标准诊断精神障碍并提供时点或最长12个月患病率。
- 使用JBI患病率研究质量评价工具和偏倚风险工具评估研究质量,采用随机效应meta分析合并患病率,通过meta回归分析异质性。
- 已在PROSPERO注册(CRD42018085216)。
主要发现
- 任何当前精神障碍的平均患病率为76.2%(95%CI 64.0%至86.6%)。
- 酒精使用障碍患病率36.7%(95%CI 27.7%至46.2%),药物使用障碍21.7%(95%CI 13.1%至31.7%)。
- 精神分裂症谱系障碍患病率12.4%(95%CI 9.5%至15.7%),重性抑郁12.6%(95%CI 8.0%至18.2%)。
- 研究间患病率存在显著异质性,部分由抽样方法、研究地点和参与者性别分布解释。
关键数值与推荐
- 任何当前精神障碍平均患病率76.2%(95%CI 64.0%至86.6%)。
- 酒精使用障碍36.7%(95%CI 27.7%至46.2%),药物使用障碍21.7%(95%CI 13.1%至31.7%)。
- 精神分裂症谱系障碍12.4%(95%CI 9.5%至15.7%),重性抑郁12.6%(95%CI 8.0%至18.2%)。
临床怎么用
- 公共卫生和政策干预应依据无家可归者精神疾病患病模式与程度设计。
- 服务发展需特别关注物质使用障碍和精神分裂症谱系障碍的高负担。
- 应定期审查医疗服务如何评估、治疗和随访无家可归者。
局限性
- 缺乏某些亚人群(如女性和移民)的信息。
- 缺乏未满足医疗需求的信息。
- 研究间异质性显著,部分由抽样方法、研究地点和性别分布解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Homelessness continues to be a pressing public health concern in many countries, and mental disorders in homeless persons contribute to their high rates of morbidity and mortality. Many primary studies have estimated prevalence rates for mental disorders in homeless individuals. We conducted a systematic review and meta-analysis of studies on the prevalence of any mental disorder and major psychiatric diagnoses in clearly defined homeless populations in any high-income country. METHODS AND FINDINGS: We systematically searched for observational studies that estimated prevalence rates of mental disorders in samples of homeless individuals, using Medline, Embase, PsycInfo, and Google Scholar. We updated a previous systematic review and meta-analysis conducted in 2007, and searched until 1 April 2021. Studies were included if they sampled exclusively homeless persons, diagnosed mental disorders by standardized criteria using validated methods, provided point or up to 12-month prevalence rates, and were conducted in high-income countries. We identified 39 publications with a total of 8,049 participants. Study quality was assessed using the JBI critical appraisal tool for prevalence studies and a risk of bias tool. Random effects meta-analyses of prevalence rates were conducted, and heterogeneity was assessed by meta-regression analyses. The mean prevalence of any current mental disorder was estimated at 76.2% (95% CI 64.0% to 86.6%). The most common diagnostic categories were alcohol use disorders, at 36.7% (95% CI 27.7% to 46.2%), and drug use disorders, at 21.7% (95% CI 13.1% to 31.7%), followed by schizophrenia spectrum disorders (12.4% [95% CI 9.5% to 15.7%]) and major depression (12.6% [95% CI 8.0% to 18.2%]). We found substantial heterogeneity in prevalence rates between studies, which was partially explained by sampling method, study location, and the sex distribution of participants. Limitations included lack of information on certain subpopulations (e.g., women and immigrants) and unmet healthcare needs. CONCLUSIONS: Public health and policy interventions to improve the health of homeless persons should consider the pattern and extent of psychiatric morbidity. Our findings suggest that the burden of psychiatric morbidity in homeless persons is substantial, and should lead to regular reviews of how healthcare services assess, treat, and follow up homeless people. The high burden of substance use disorders and schizophrenia spectrum disorders need particular attention in service development. This systematic review and meta-analysis has been registered with PROSPERO (CRD42018085216). TRIAL REGISTRATION: PROSPERO CRD42018085216.
引用
- Gutwinski S, Schreiter S, Deutscher K, et al. The prevalence of mental disorders among homeless people in high-income countries: An updated systematic review and meta-regression analysis. PLoS Med. 2021. PMID: 34424908. doi:10.1371/journal.pmed.1003750
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。